van Akkooi, Alexander C. J. http://orcid.org/0000-0002-3262-6935
Zijlker, Lisanne P.
Wouters, Michel W. J. M.
Funding for this research was provided by:
University of Sydney
Article History
Accepted: 2 March 2022
First Online: 9 April 2022
Declarations
:
: Open Access funding enabled and organized by CAUL and its Member Institutions.
: Alexander C.J. van Akkooi reports advisory board and consultancy honoraria (all paid to institute and unrelated to current work) from Amgen, Bristol-Myers Squibb, Novartis, 4SC, Merck-Pfizer, MSD-Merck, Pierre Fabre, Sanofi and Sirius Medical, and research grants from Amgen and Merck-Pfizer (all paid to the institute and unrelated to the current work). Michel W.J.M. Wouters declares a research grant from Novartis. Lisanne P. Zijlker declares that she has no conflicts of interest that might be relevant to the contents of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: All data included in this review are available from peer-reviewed and published articles.
: Not applicable.
: AvA has drafted this manuscript at the invitation of the editors of Springer Healthcare. AvA, LZ and MW were involved in the revision and final approval of the manuscript.